OPK Opko Health, Inc.

7.63
+0  (1%)
Previous Close 7.52
Open 7.60
Price To book 2.01
Market Cap 4.26B
Shares 558,221,000
Volume 3,385,178
Short Ratio 13.87
Av. Daily Volume 4,442,760

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial to be initiated in early 2018.
TT401 (oxyntomodulin)
Obesity and diabetes
Phase 3 trial to be initiated 2H 2017.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 initiation announced December 30, 2016.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 safety data due 1H 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 2H 2017.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. Xenetic Biosciences’ PolyXen™ Platform Technology Accepted for Poster Presentation at the 13th Annual Protein Engineering Summit (PEGS) Boston
  2. 3 Beaten-Up Healthcare Stocks: Are They Bargains?
  3. ETFs with exposure to OPKO Health, Inc. : April 17, 2017
  4. Xenetic Biosciences Expands Executive Management Team with Appointment of James F. Parslow, MBA, CPA as Chief Financial Officer
  5. OPKO Health, Inc. :OPK-US: Earnings Analysis: 2016 By the Numbers : March 30, 2017
  6. OPKO Health, Inc. breached its 50 day moving average in a Bullish Manner : OPK-US : March 29, 2017
  7. ChromaDex Appoints Steven D. Rubin, J.D., to its Board of Directors
  8. 3 Stocks That Could Double Your Money
  9. Opko Gets Orphan Status for Genetic Disorder Drug
  10. OPKO Receives FDA Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder
  11. OPKO Health's GeneDx to have Significant Presence at ACMG 2017
  12. OPKO Health to Participate in the Barclays Global Healthcare Conference
  13. Better Buy: Myriad Genetics, Inc. vs. Opko Health, Inc.
  14. Biotech's Rally in 2017 Stumbles on Pricing Concerns: Today's Research Reports on Opko Health and Cerus
  15. OPKO Health (OPK) Launches Prenatal Testing Tool ClariTest
  16. OPKO Receives EU Orphan Drug Status for its New Oligonucleotide to Treat Genetic Neurological Disorder 
  17. Opko Health subsidiary launches prenatal testing tool
  18. OPKO Health, Inc. :OPK-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017
  19. OPKO Subsidiary GenPath Women’s Health Announces the Availability of ClariTest™